Loading...

PHIO PHIO PHARMACEUTICALS CORP Product Launches 8-K Filing

PH P

PH

PHIO PHARMACEUTICALS CORP

(PHIO)

2025 8-K

Clinical Trial Enrollment

Financial Results Report

Warrant Exercise Agreement

Treatment Progress Update

Annual Meeting Outcomes

Conference Presentation

Quarterly Results Report

Warrant Exercise

Market Expansion

Clinical Trial Progress

Financial Statements

Clinical Trials

Accountant Change

Product Advancement

Financial Results

Board Appointment

Clinical Study Results

Clinical Trial Update

Financial Results

Clinical Data Presentation

Financial Results

Appointment of Chief Financ...

Compliance regained with re...

Entry into Material Definit...

Termination of Purchase Agr...

Reverse Stock Split

Annual Meeting Approval

Announcement of Safety Moni...

Purchase Agreement with Tri...

Financial Results

Financial Results

Agreement with Existing War...

Financial Results and Clini...

Clinical Trial Announcement

Financial Results

Annual Meeting and Incentiv...

Securities Purchase Agreements

Clinical Trial Initiation

FDA Clearance for Clinical ...

Financial Results

Amendment Filing

Securities Purchase Agreement

Poster Presentation Announc...

Financial Results

Closure of Silicon Valley Bank

Appointment of President an...

Compliance regained with re...

Reverse Stock Split

Special Meeting and Reverse...

External Links:

On November 3, 2025, Phio Pharmaceuticals announced a 100% tumor clearance in one patient, over 90% in another, and over 50% in a third patient with skin cancer, alongside positive safety results for their drug INTASYL PH-762 in a clinical trial.

AI Assistant

PHIO PHARMACEUTICALS CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.